3LOK | pdb_00003lok

Drug resistant cSrc kinase domain in complex with covalent inhibitor PD168393


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.48 Å
  • R-Value Free: 
    0.286 (Depositor), 0.288 (DCC) 
  • R-Value Work: 
    0.221 (Depositor), 0.223 (DCC) 
  • R-Value Observed: 
    0.225 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 3LOK

Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history

Literature

Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance

Klueter, S.Simard, J.R.Rode, H.B.Gruetter, C.Pawar, V.Raaijmakers, H.C.Barf, T.A.Rabiller, M.van Otterlo, W.A.L.Rauh, D.

(2010) Chembiochem 11: 2557-2566

  • DOI: https://doi.org/10.1002/cbic.201000352
  • Primary Citation Related Structures: 
    3LOK

  • PubMed Abstract: 

    Targeting protein kinases in cancer therapy with irreversible small-molecule inhibitors is moving to the forefront of kinase-inhibitor research and is thought to be an effective means of overcoming mutation-associated drug resistance in epidermal growth factor receptor kinase (EGFR). We generated a detection technique that allows direct measurements of covalent bond formation without relying on kinase activity, thereby allowing the straightforward investigation of the influence of steric clashes on covalent inhibitors in different resistant kinase mutants. The obtained results are discussed together with structural biology and biochemical studies of catalytic activity in both wild-type and gatekeeper mutated kinase variants to draw conclusions about the impact of steric hindrance and increased catalytic activity in drug-resistant kinase variants.


  • Organizational Affiliation
    • Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany.

Macromolecule Content 

  • Total Structure Weight: 66.28 kDa 
  • Atom Count: 4,018 
  • Modeled Residue Count: 490 
  • Deposited Residue Count: 572 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Proto-oncogene tyrosine-protein kinase Src
A, B
286Gallus gallusMutation(s): 2 
Gene Names: SRCv-Src sarcoma viral oncogene
EC: 2.7.10.2
UniProt
Find proteins for P00523 (Gallus gallus)
Explore P00523 
Go to UniProtKB:  P00523
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP00523
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Binding Affinity Annotations 
IDSourceBinding Affinity
DJK BindingDB:  3LOK IC50: min: 340, max: 2.70e+4 (nM) from 4 assay(s)

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.48 Å
  • R-Value Free:  0.286 (Depositor), 0.288 (DCC) 
  • R-Value Work:  0.221 (Depositor), 0.223 (DCC) 
  • R-Value Observed: 0.225 (Depositor) 
Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 42.09α = 78.49
b = 63.26β = 88.33
c = 74.22γ = 90
Software Package:
Software NamePurpose
MOSFLMdata reduction
SCALAdata scaling
PHASERphasing
REFMACrefinement
PDB_EXTRACTdata extraction
MAR345dtbdata collection

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2010-12-22
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2023-11-01
    Changes: Data collection, Database references, Derived calculations, Refinement description
  • Version 1.3: 2024-11-13
    Changes: Structure summary